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Withanolide A: synthesis and structural requirements
for neurite outgrowth†
Raphael Liﬀert,‡a Johannes Hoecker,‡a Chandan K. Jana,§a Tom M. Woods,{a
Patrick Burch,a Henning J. Jessen,ka Markus Neuburgerb and Karl Gademann*a
The exploration of diﬀerent routes leading to the stereoselective synthesis of the neuritogenic steroid
withanolide A is reported in full detail. Notable features of the synthesis include a Corey–Seebach
homologation, a vinylogous aldol reaction, a singlet oxygen Schenck-ene reaction, and ﬁnally, a late-
stage Wharton transposition. Semi-synthetic elaboration of the natural product resulted in 15
derivatives allowing a better understanding of its inherent reactivity pattern as well as its biological
properties related to neuronal diﬀerentiation and neurite outgrowth.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder char-
acterized by amyloid plaque formation, dysfunctional neurons
and loss of cognitive functions.1a The number of people
suﬀering from this disease is increasing at an alarming rate,
with death occurring approximately 9 years aer diagnosis.2 The
pathogenesis of AD is yet to be fully understood, and both
genetic and environmental factors have been suggested to
contribute to its progress.3 Currently, dementia is treated
mainly with acetylcholine esterase inhibitors that delay the
progression rather than actually restore brain function. Due to
the prevalence of AD and the nonexistence of long-term thera-
pies, there is a strong requirement to nd new drug leads for the
therapy of AD and associated diseases.1b
The roots ofWithania somnifera, also known as ashwagandha
(Indian ginseng), are utilized in traditional ayurvedic medicine
to improve the cognitive performance of the elderly.4 In addi-
tion, they have been frequently used in the context of anti-aging,
memory reconstruction4 and more recently as cognitive
enhancers5 for healthy subjects. Withanolide A (1) isolated from
the roots of Withania somnifera,6 constitutes one of the most
active compounds in the methanolic extracts of ashwagandha
and has been demonstrated to possess strong pharmacological
properties with regard to axonal outgrowth, regeneration of
neurites and recovery of damaged synapses in mice.4,7 This
pharmacological evidence encouraged us to further investigate
this natural product beyond the recently completed rst total
synthesis of the steroid 1,8 and to prepare derivatives for
structure activity relationship (SAR) studies.
Withanolide A is a highly oxygenated steroidal lactone
oﬀering several challenges in the context of its synthesis (Fig. 1).
The natural product family of the withanolides is characterized
by an A, B, C, D steroid ring system and a lactone side chain
(SC).9,10 Withanolide A possesses a reactive enone moiety in the
A ring, an epoxy alcohol in the B ring, as well as a tetrasub-
stituted unsaturated lactone as a side chain. The main synthetic
challenges arise from the stereoselective construction of
the side chain and the oxidation pattern of the A and B ring and
the diastereoselective instalment of a tertiary alcohol at C-20.
Departing from a cheap and commercially available starting
material, we chose pregnenolone 2 for our synthetic
endeavours.
In this edge article, we report in full detail on diﬀerent
synthetic approaches to the target withanolide A culminating in
the rst synthesis of this steroid. In addition, semi-synthesis
Fig. 1 Structures of withanolide A (1) and pregnenolone (2).
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studies not only allowed the reactivity of the diﬀerent parts of
the steroidal structure to be assessed, but also enabled the
generation of 15 derivatives resulting in detailed SAR studies on
neuronal diﬀerentiation and neurite outgrowth in human
neuroblastoma cells.
Results and discussion
Evaluation of diﬀerent routes to withanolide A
We initially identied the presence of the a,b-unsaturated
lactone in the side chain as the most labile fragment of
withanolide A (1), which led us to embark on a strategy
involving late instalment of this pyranone. It was further
anticipated that we could use a procedure developed by Ike-
kawa and co-workers11 to form the lactone side chain motif
from a simple steroidal aldehyde precursor by a vinylogous
Mukaiyama aldol reaction in the last step, aer the B and A
rings had been completed.
The approach started with the known homologation
required for the side chain by a Corey–Seebach umpolung
reaction.12 Therefore, the 3b-OH group of commercially avail-
able pregnenolone (2) was protected as its TBS ether and
treatment of the resulting ketone with lithiated dithiane aﬀor-
ded the tertiary alcohol 3 (Scheme 1) in 95% yield (dr 15 : 1).
Several methods were investigated to cleave the dithiane moiety
in 3, with the main concern being the stability of the TBS pro-
tecting group. Methods such as HgCl2, NBS and I2 both with
and without addition of base were largely unsuccessful and
resulted in either the loss of the TBS group as well as the
dithioacetal or more complex mixtures. However, treatment of
dithiane 3 with NCS in a CH2Cl2–H2O mixture in an open vessel
at room temperature aﬀorded the desired a-hydroxy aldehyde in
a good yield. Protection of the C-20 tertiary alcohol as its MOM
ether 4 was achieved by treating a solution of the alcohol and
N,N-diisopropylethylamine (DIPEA) with MOMI and reuxing
the reaction overnight (in 69% over 2 steps). The eﬃciency of
the reaction was found to be dependent on the quality of the
starting materials, in particular, NaI was dried under high
vacuum at 100 C for several hours and MOMCl was freshly
distilled before use. A simple ltration through a short pad of
silica was suﬃcient to provide material for the next step.
Reduction of aldehyde 4 with NaBH4 in MeOH proceeded
uneventfully and furnished the desired alcohol as a white solid,
which was used directly in the next step. Treatment of the
alcohol with NaH followed by addition of PMBCl and a catalytic
amount of tetrabutylammonium iodide (TBAI) aﬀorded the
desired diﬀerentially protected triol 5.
With the homologated triol 5 in hand the stage was set to
target the functionalization on the B ring. Epoxidation of the
double bond proceeded smoothly aﬀording a 4.1 : 1 diaste-
reomeric ratio of the desired a-epoxide 5 in 71% yield over
three steps. Performing the reaction at 0 C slightly improved
the selectivity, but lower temperatures (e.g. 15 C) reduced
the rate of reaction. Following a method of Sharpless and
Lauer for the oxidative opening of epoxides,13 reduction of
(PhSe)2 with NaBH4 in EtOH followed by addition to the MOM
protected epoxide and further treatment with H2O2, aﬀorded
the desired allylic alcohol 6 in 48% yield accompanied by
recovered starting material. The undesired b-epoxide was not
reactive towards these conditions and separation was easily
achieved. Allylic alcohol 6 was sensitive to acidic conditions
and was prone to rearrange to the thermodynamically more
stable trisubstituted olen. The allylic alcohol 6 was then
further transformed to the epoxy alcohol by simple treatment
Scheme 1 Approach towards the synthesis of MOM-protected withanolide A derivative 11.
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with mCPBA in CH2Cl2. This directed epoxidation (by the
tertiary OH group) was found to be completely selective and
high yielding and completed the functionalization of the B-
ring. Deprotection of the TBS group by treatment with tetra-
butylammonium uoride (TBAF) furnished compound 7
bearing a free OH group at C3.
For the subsequent transformation of the A ring to the
desired enone, allylic oxidation reactions turned out to be
unsuccessful,14 and therefore Saegusa oxidation was chosen
instead.15 Aer oxidation of the secondary OH group by TPAP,
the formed TIPS enol ether was treated with 1 equivalent of
Pd(OAc)2 in CH3CN and the desired a,b-unsaturated ketone 8
was isolated in 43% yield (over three steps). Attempts to
reduce the amount of Pd(OAc)2 employed by adding benzo-
quinone as a co-oxidant led to poor yields of the desired
product. Epoxidation of the unsaturated ketone under basic
conditions gave the bis-epoxide in 54% yield with complete
diastereoselectivity. K2CO3 was found to be the best choice of
base; stronger bases such as NaOH and KOtBu gave complex
mixtures of products. With the keto epoxide in hand the stage
was set for the Wharton transposition. Wharton's original
conditions (N2H4$H2O, AcOH) aﬀorded poor yield of the
desired allylic alcohol.16 However, in 1989 Dupuy and Luche
reported modied conditions for the Wharton transposition
using basic conditions,17 and in such a way, the conversion to
the allylic alcohol was improved. Subsequent deprotection of
the PMB protecting group using 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) proceeded smoothly and aﬀorded triol 9
in a 50% yield over the two steps. The primary and secondary
diols were then oxidized simultaneously with TPAP, NMO to
complete the A ring functionalities and to furnish the desired
C-22 aldehyde 10. In order to complete the synthesis of
withanolide A (1), the side chain lactonization was evaluated
next. However, despite using a variety of conditions, the nal
lactonization to 11 could not be performed successfully. It
is likely that the presence of the enone in the A ring is
detrimental to this approach, which therefore had to be
abandoned.
Preparation of withanolide A
Having realized the sensitivity of the A ring, both from the
unsuccessful synthetic attempt as discussed above, and from
the ease of its functionalization in the context of semi-synthesis
studies (vide infra), we sought to introduce this enone last in the
synthetic sequence. In addition, these studies hinted at the
stability of the side chain lactone, which led us to choose its
early instalment (Scheme 2). Therefore, following the procedure
developed by Ikekawa and co-workers,10a,11 the aldehyde 4 was
reacted with the vinylogous enolate from ethyl 2,3-dimethylbut-
2-enoate and LiHMDS in a mixture of THF and DMPU via a
stereoselective aldol reaction to deliver the unsaturated lactone
side chain 12 in very good yield and stereoselectivity (87%, dr
93 : 7). Again, protection of the tertiary alcohol as the MOM
ether was found to be key for this transformation. Unselective
side-reactions during exposure to strong bases during its
introduction were avoided, and the relatively small size of the
MOM group meant that the unhindered nucleophilic attack of
the formed enolate on the aldehyde was possible.
We next proceeded to install the correct oxidation pattern
in the B ring of withanolide A. The challenge as previously
described consisted in the regioselective instalment of the
epoxy alcohol in the presence of the unsaturated lactone.
Having struggled with limitations associated with phenyl-
selenium-chemistry as detailed above, we recognized the
singlet oxygen mediated photo-oxygenative olen migration
(Schenck-ene reaction18) as a straightforward method19 for the
preparation of the allylic alcohol 13 from an unfunctionalized
olen. Therefore, olen 12 was allowed to react with singlet
oxygen generated in situ from O2 in the presence of meso-tet-
raphenylporphyrin (TPP) as sensitizer under irradiation with
Na-light. The formed hydroperoxide was in situ reduced by
PPh3 to the allylic alcohol 13 in good yield (61%). Directed
epoxidation of allylic alcohol 13 mediated by mCPBA pro-
ceeded as anticipated to provide, aer removal of all protecting
groups by exposure to HCl, the desired epoxy alcohol 14 in
excellent yield.
It should be pointed out that we have, by design, chosen to
avoid any protecting groups for the remaining elaboration of
triol 14 therefore exploiting the inherent reactivity of this
steroid derivative. The nal installation of the correct oxidation
pattern in the A ring started by oxidation of the triol 14 rst by
TPAP and NMO and second by exposure to 2-iodoxybenzoic acid
(IBX)20 to provide the corresponding enone 15 (77%). The
unsaturated ketone 15 was then converted with basic aqueous
H2O2 (Triton B)21 to the epoxy ketone. The stage was again set
Scheme 2 Synthesis of withanolide A (1) from aldehyde 4.
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for the Wharton transposition on the epoxy ketone substrate.
Therefore, the intermediate was subjected to reaction with
hydrazine (N2H4$HCl) in the presence of base to furnish the
rearranged allylic alcohol.17 This reaction proceeded smoothly
to give, aer subsequent oxidation by pyridinium dichromate
(PDC), withanolide A (1) in good yield (30% over three steps).
All analytical data (1H and 13C NMR, optical rotation, UV,
m.p.) for the synthetic and isolated natural product were found
to be in full agreement. The nal proof of identity of the
synthetic and isolated natural sample of 1 was established by
co-injection and analysis of natural and synthetic samples
by HPLC.
Semi-synthesis of new derivatives of withanolide A
In order to access additional derivatives for biological studies,
we initiated semi-synthesis studies on withanolide A (1). This
steroidal lactone was therefore isolated from the dried and
powdered roots of Withania somnifera (ashwagandha) by a
modication of a known procedure.6 Aer an extensive survey of
diﬀerent approaches commonly employed in semi-synthesis to
functionalize withanolide A (1), we found that only the A ring
was susceptible to chemical modication. In addition, A ring
derivatives bearing e.g. a 3b-hydroxy group like sominone—an
aglycon of withanoside IV—were found to display neuritogenic
properties as shown from the work of Tohda and co-workers,22
lending further support to the hypothesis that compounds with
variations in this ring may retain biological activity.
We rst targeted the regioselective 1,2-reduction of with-
anolide A resulting in the allylic alcohol 16, which was envi-
sioned to serve as a building block for a variety of new
functionalities at C-1. The reduction was performed under
Luche conditions,23 using CeCl3 and NaBH4 in a mixture of
MeOH and CHCl3 in 75% yield with complete diaster-
eoselectivity (Scheme 3). Surprisingly, the same stereochemical
outcome was observed when using simple NaBH4 without
additional CeCl3 to coordinate the ketone function, as estab-
lished by an X-ray crystal structure analysis in an earlier study.8
Unfortunately, all attempts to further functionalize the C-1
hydroxy group or acetylation reactions were unsuccessful.
Regioselective hydrogenation of the 2,3-double bond was per-
formed by using 2 mol% Crabtree's catalyst under a hydrogen
atmosphere of 10 bar to obtain the saturated alcohol 17.
Due to the problems associated with the manipulation of the
allylic alcohol 16, a new strategy for the derivatization of the
natural product needed to be developed. Tohda et al. showed in
their studies on sominone that steroids bearing a C3-OH group
can serve as useful intermediates.22 Therefore we targeted a
synthetic route from withanolide A to C3-OH derivatives, as
shown in Scheme 4. The synthetic plan relied on epoxidation of
withanolide A (1) followed by epoxide opening under reductive
conditions, which was used in the context of B ring function-
alization (see 5 to 6, Scheme 1). It should be pointed out that
again no protecting groups were introduced and that these
reagents have been found to be compatible with the functional
group manifold present in the A and B rings and the side chain
lactone.
We rst evaluated the epoxidation of withanolide A (1) by
using the conditions developed in the course of the total
synthesis. Exposure of steroid lactone 1 to aqueous H2O2 in the
presence of Triton B aﬀorded epoxide 18 in 48% yield on small
scale. Unfortunately, the reaction was dependent on the scale,
and the use of 100 mg of 1 resulted in a dramatic loss of
material (11% yield). Aer extensive investigation of diﬀerent
conditions (solvent, base and oxidizing reagents)24 we found the
uoride-promoted epoxidation of a,b-unsaturated carbonyl
compounds described by Yoshikoshi and co-workers was
compatible with our system.25 By using their protocol, the use of
TBAF as base and H2O2 or tert-butyl hydroperoxide (tBuOOH) as
oxidation reagent was found to be superior. These conditions
improved the yield reliably to 84% (on a 150 mg scale), with
CH2Cl2 as solvent and tBuOOH as oxidant.
The organoselenium-mediated reduction of a,b-epoxy
ketone 18 to the corresponding b-hydroxy ketone was investi-
gated next. Alcohol 19 was obtained in good yields on adding an
ethanolic solution of the active reagent (Na[PhSeB(OEt)3]) and
AcOH to a solution of epoxy ketone 18 in CH2Cl2.26 The chemical
shi of the equatorial C3-H in 19 was found to be at 4.11 ppm,
whereas the axial proton reported for the C3 diastereomeric
natural product27 resonates at 4.91 ppm. This large diﬀerence
might be caused by the inuence of the neighbouring hydroxyl
group on the axial proton and could be observed later for the
allylic alcohols 22 and 24 as well. Eﬃcient acetylation of alcohol
19 under standard conditions (Ac2O, DMAP, Et3N in CH2Cl2)
delivered acetate 20 in 77% yield without any detectable amount
of eliminated side-product. This example demonstrates the
feasibility of introducing carboxylate esters of choice at this
position. Reduction of ketone 19 was performed using NaBH4
and aﬀorded a new baseline spot by TLC. UPLC-MS conrmed
formation of tetraol 21, but the isolation of this hydrophilic
compound turned out to be diﬃcult.28 Finally, work-up with a
saturated solution of Rochelle salt liberated tetraol 21 and
allowed the characterization of its structure by NMR spectros-
copy. The stereochemical outcome of 21 was anticipated from
the NaBH4 mediated reduction of withanolide A (1) and could
be conrmed by NOESY NMR spectroscopy. The structuralScheme 3 Regioselective reduction of withanolide A.
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assignment was supported by NOE cross peaks of H-1 with H-19
and H-2 and H-4, respectively.
Concerning the targeted introduction of substituents at C3,
another possibility could be the transformation of epoxy ketone
18 to allylic alcohol 22 (Scheme 4). For this manipulation, the
Wharton carbonyl transposition was investigated using condi-
tions as discussed earlier. Consequently, epoxy ketone 18 was
treated with NH2NH2$HCl in the presence of Et3N in CH3CN,16
but no product formation was observed. Typical acidic condi-
tions with NH2NH2$H2O and AcOH for Wharton transposition
are reported in various publications and O'Doherty and Wang
described a method using more equivalents of both reagents
NH2NH2$H2O and AcOH to improve the yield.29 They also noted
that a protic solvent can be favourable for certain substrates.
Due to the low solubility of 18 in methanol, the reaction was
successfully conducted in a 1 : 1 mixture of methanol and
CH2Cl2 to obtain the allylic alcohol 22 in 61% yield aer 3 h at
room temperature. The structure of alcohol 22 was conrmed
by X-ray analysis of the crystal structure and the conguration of
the 3a-OH group was retained from the epoxidation step.
Next, we investigated the introduction of functional groups
at the newly formed secondary alcohol in order to probe if
alcohol 22 can be attached to various residues such as, for
example, sugars known from the studies on sominone by Tohda
and co-workers. Acetylation of allylic alcohol 22 was performed
again under standard acetylation conditions and aﬀorded
acetate 23 in good yield. This indicates that alcohol 22 is also a
feasible precursor for further manipulations. Inversion of the
C3 hydroxyl group in 22 was accomplished using the Mitsunobu
procedure. Esterication with para-nitrobenzoic acid, followed
by saponication with aqueous NaOH in the presence of tetra-
butylammonium hydroxide (TBAH) as phase-transfer catalyst
aﬀorded 3b-allylic alcohol 24 in 50% yield.
Additionally, the double bond of allylic alcohol 22 was
reduced with 10 mol% Pd on activated charcoal. Quantitative
conversion provided alcohol 25 as an inseparable 1 : 1 mixture
with the isomerized saturated ketone 14a (Scheme 5), an
intermediate obtained in our synthesis of 1 (see Scheme 2).30
Given that we were interested in alcohol 25, Crabtree's catalyst
turned out to be eﬃcient for the hydrogenation of 22 to yield
alcohol 25 quantitatively without the isomerized product.
Oximes of withanolide A as prodrugs may improve the
solubility as well as the bioavailability in vivo. Additionally,
oximes were found to be the only possibility to modify the C1
position of natural product 1 (Scheme 6). The oximes 26–30
were easily obtained by heating withanolide A 1 or the derived
epoxide 18 and the corresponding hydroxylamine hydrochlo-
ride in pyridine at 70 C for 1 to 2 days in good yields.
Biological evaluation
The natural product 1 and several semi-synthetic derivatives
were tested in order to determine their neuritogenic properties
according to the previously published methods.7a,8 Human SH-
SY5Y neuroblastoma cells (4  104 cells per cm2) were grown on
collagen I coated 24-well plates in minimal essential medium
(MEM) with 5% fetal bovine serum (FBS). Aer incubation for 4
days in the presence of the corresponding compounds (1 mM,
Scheme 4 Semi-synthetic transformations of withanolide A to access A ring derivatives without the enone moiety.
Scheme 5 Hydrogenation of allylic alcohol 22.
This journal is ª The Royal Society of Chemistry 2013 Chem. Sci., 2013, 4, 2851–2857 | 2855
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0.1% DMSO), the cells were examined under a phase contrast
microscope aer xation (5% formaldehyde in PBS buﬀer
solution), stained (modied Giemsa stain), and the diﬀerenti-
ated cells were counted. For each compound nine pictures from
random areas of three diﬀerent wells were taken (for repre-
sentative micrographs see ESI†). At least 500 cells were counted
for each individual compound. The criterion for a diﬀerentiated
cell was at least one neurite with a length of more than 50 mm. In
control experiments DMSO (0.1%) was used as a negative
control. The results are summarized in Fig. 2.
While it is diﬃcult to draw quantitative conclusions from the
biological assays, several facts became apparent: compounds
16, 22, 24, and 26 showed similar activities when compared to
withanolide A with regard to neurite outgrowth stimulating
activity in SH-SY5Y cells. The compounds 18, 23, and 27–30
showed in fact less activity than withanolide A, to the extent that
some compounds can be hardly distinguished from the solvent
control in these phenotypic assays. It appears that there is a
correlation between the size of the attached group and activity.
For example, the hydroxylamine 26 shows increased activity
than the corresponding and sterically more demanding oximes
27–30. The same trend was observed for allyl alcohol 22 and its
acetate 23. Additionally, the chemically reactive enone moiety of
withanolide A in the A ring might not be required for neuro-
active properties, as the allylic alcohols 16 and 22 retained
activity.
Conclusions
In conclusion, we have developed the rst successful synthesis
of the pharmacologically important steroid withanolide A by
adjusting the route based on the understanding of the inherent
reactivity of the natural product by semi-synthesis studies.
Notable features of this synthesis include (1) a highly diaster-
eoselective Schenck-ene reaction, (2) a minimal protecting
group strategy exploiting the inherent reactivity pattern in the
endgame and (3) a Wharton transposition for the A ring
formation. Further, we have synthesised more than 15 deriva-
tives of withanolide A directly from the isolated natural product.
Therefore, we developed two new synthetic routes that allow the
generation of a hydroxyl group at C3 and thereby open the door
for attachment of a variety of functionalities. Both key inter-
mediates, the b-hydroxy ketone 19 and the allylic alcohol 22,
were synthesised in high yields and full diastereoselectivity
using simple reaction conditions in two steps from 1.
In addition, biological studies of neurite outgrowth in
human SH-SY5Y cells demonstrated the dependence of neu-
ritogenic properties on the size rather than the functionality in
the A ring of the evaluated compounds. Three compounds
indicated a comparable or higher neurite outgrowth activity in
cell assays than withanolide A itself. Further investigations
towards the modication of functional groups at C-3 of with-
anolide A would probably give access to more sophisticated
candidates and allow for the manipulation of properties such as
solubility or bioavailability.
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